With patients often facing grim prognoses, and insurers relatively powerless to negotiate prices or deny coverage, the cost of treatments have little impact on demand.
Dichloroacetate (DCA) committs "immortal" cancer cells to a natural death while leaving normal cells unharmed - but DCA is not patentable, so pharmaceutical companies have no incentive to begin clinical trials...